Amundi
NAGE

Amundi’s Niagen Bioscience NAGE Stock Holding History

Amundi’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.7K Buy
+12,748
New +$51.7K ﹤0.01% 2056

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Amundi's NAGE Position: Q2 2026 in Review

Amundi opened a new position in Niagen Bioscience (NAGE) in Q2 2026: 12,748 shares worth $40.7K. The stake represents ﹤0.01% of the portfolio and ranks #2056 among its holdings.

140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Amundi held 12,748 shares of Niagen Bioscience worth $40.7K as of Q2 2026.
  • Niagen Bioscience was a new Amundi position in Q2 2026.
  • Niagen Bioscience made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #2056 holding.
  • 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.